Introductions Chair,
ACRHD
Acting
Executive Secretary, ACRHD, FDA
Director, Div. of Reproductive and
Urologic Drug Products (DRUDP), FDA
Issue: The public health issues, including the safety and potential clinical benefit, associated with combining folic acid and an oral contraceptive into a single combination product.
Folate Nutrition and Metabolism and Influence Barry Shane, Ph.D.
on Neural Tube Defects (NTDs) Professor,
Dept. of Nutritional
Sciences and Toxicology
Folic Acid and Safety Patrick
J. Stover, Ph.D.
Associate
Professor of
Nutritional
Biochemistry
Folic Acid Fortification in the
Planning, Implementation, and Monitoring Lead Scientist for Nutrition
Center for Food Safety and
Applied Nutrition (CFSAN),
FDA
Assessing the Impact of Fortification on the Joe Mulinare, M.D., MSPH
Epidemiology of NTDs
and Developmental Disabilities Centers for Disease Control
and Prevention (CDC)
Folic Acid Supplementation and
Fortification Michiel Van den Hof, M.D.
in
What is the Minimum Effective Dose of Folic Acid James L. Mills, M.D., M.S.
for Preventing NTDs? Chief, Pediatric Epidemiology Section
Epidemiology Branch
Div. of Epidemiology, Statiststics and Prevention Research, NICHD, NIH
Proposal
Background and Overview Andrew
J. Friedman, M.D.
Director, Women’s Health
Care Research Ortho-McNeil Pharmaceutical, Inc.
Neural Tube Defects: Efficacy and Safety of Godfrey
P. Oakley, Jr., M.D., MSPM
Folic Acid
Visiting Professor, Dept. of Epidemiology
Need for Increased Folic Acid Intake Among Anna
Maria Siega-Riz, Ph.D., R.D.
Reproductive Age Women Associate
Professor of Maternal and Child
Health and Nutrition
Oral Contraceptive Use, Pregnancy Intendedness Andrew
M. Kaunitz, M.D.
and Folic Acid Intake Professor
and Assistant Chairman
University
of
Summary and
Conclusion Andrew
J. Friedman, M.D.